Global Human Microbiome Market Report by Application (Therapeutics, Diagnostics) Disease (Obesity, Diabetes, Autoimmune Disorders, Cancer, Gastrointestinal Disorders, Central Nervous System Disorders, Other Diseases) Product (Probiotics, Prebiotics, Symboitics, Other Products), Countries and Company Analysis, 2024-2032

Global Human Microbiome Market Analysis

Global Human Microbiome Market Outlook

A group of bacteria that live on and in the human body is known as the human microbiome. It is home to a variety of creatures, including as viruses, bacteria, fungus, bacteriophages, and protozoa. The microbiota, which may weigh as much as five pounds, aids in digestion, produces vitamins B and K, protects against other pathogenic bacteria, and regulates our immune system. Within and outside of our bodies, the human microbiome is a market with enormous potential that includes bacteria, viruses, eukaryotes, and archaea. Growing knowledge of prebiotics and probiotics and their function in preventative health measures is predicted to drive a large increase in demand for these supplements. The aging population, the rise in lifestyle-related illnesses, and government support for programs like "the Earth Microbiome" and "the Human Microbiome Project" are some of the factors contributing to this growth. These programs give industry participants the chance to conduct research and create new goods, which will propel market expansion over the course of the projection.

The study of the human microbiome is important and could completely change the medical field. It has a direct impact on diseases like diabetes and is linked to the aging population and an increase in lifestyle-related disorders. According to data from the International Diabetes Federation, 52.7 million Europeans between the ages of 20 and 79 have diabetes, and that number is predicted to rise to 69 million by 2045. The impact of butyrate-producing bacteria and the diversity of gut microbes on type 2 diabetes risk and insulin resistance is noteworthy, indicating the importance of the human microbiome on overall health. The increase in ailments linked to a lifestyle change, including diabetes, will drive the market's growth in the next years.

Driving forces for Human Microbiome Market

The growing number of elderly people and the rising burden of lifestyle-related disorders are major drivers of this market's growth- For example, according to data from the International Diabetes Federation for 2021, 52.7 million individuals in Europe between the ages of 20 and 79 have diabetes, and by 2045, that figure is predicted to rise to 69 million. The market is anticipated to develop due to increased gut microbial diversity, particularly more butyrate-producing bacteria, which benefits insulin resistance and type 2 diabetes risk. It also increases the burden of lifestyle diseases like diabetes.

Government programs and increased funding initiatives to promote this research are high-impact key factors expected to stimulate market expansion - For example, according to the National Institute of Health, the Federal Government of the United States spent USD 864 million in 2021 and is projected to spend USD 903 million in 2022 on research and development of the microbiome. This information was reported in May 2022. Over the course of the projection period, the government's investment is driving the market's growth. However, during the course of the projection period, the market's expansion is projected to be constrained by a lack of thorough research and strict government regulations.

North American Human Microbiome Market

The largest market for human microbiomes in North America is the United States, followed by Canada. In the United States, the American Cancer Society projects that 1,918,030 new cases of cancer will be diagnosed in 2022. Data from Globocan 2020 indicate that there are currently 274,364 new cases of cancer; by 2040, that number is predicted to rise to 400,564. The predicted growth in the market is attributed to the increasing prevalence of cancer and the impact of gut microbiota in modulating tumor therapy, enhancing immunotherapy response, and mitigating the side effects of chemotherapeutic medications. A rising number of research studies and the assistance of regulatory authorities for investigation provide additional evidence for this market expansion. Two Live Biotherapeutics, MRx0005 and MRx0029, were approved by the FDA in February 2022 as investigational new medicines (INDs) by 4D Pharma plc to treat Parkinson's disease. It is anticipated that these approvals will have a favorable effect on the market's growth.

Human Microbiome Company Overview

DuPont, Evelo Biosciences Inc., Finch Therapeutics Group Inc., Ginkgo Bioworks, Seres Therapeutics, AOBiome, Astarte Medical, Axial Biotherapeutics Inc. and Osel Inc. are major market players of the Global Human Microbiome Industry.

Human Microbiome Company News

In April 2023,The FDA in the United States has approved VOWSTTM (fecal microbiota spores, live-brpk), an oral microbiota-based therapeutic, to prevent recurrence of C. difficile infection (CDI) in adults after antibacterial treatment for recurrent CDI (rCDI). The announcement was made by Seres Therapeutics, Inc. and Nestlé Health Science. This aided in the business's product line expansion.

In April 2023,Funding totaling USD 106.5 million was raised by Vedanta Biosciences to develop a pipeline of specific bacterial consortia medicines. The money raised will help the business fund a crucial Phase III trial of VE303, which is intended to stop CDI from happening again.

Application - Market breakup into 2 Viewpoints

1. Therapeutics
2. Diagnostics

Disease – Market breakup into 7 Viewpoints

1. Obesity
2. Diabetes
3. Autoimmune Disorders
4. Cancer
5. Gastrointestinal Disorders
6. Central Nervous System Disorders
7. Other Diseases

Product – Market breakup into 4 Viewpoints

1. Probiotics
2. Prebiotics
3. Symboitics
4. Other Products

Geography – Global Human Microbiome breakup of 25 Countries

North America

1. United States
2. Canada

Europe

1. France
2. Germany
3. Italy
4. Spain
5. United Kingdom
6. Belgium
7. Netherlands
8. Turkey

Asia Pacific

1. China
2. Japan
3. India
4. Australia
5. South Korea
6. Thailand
7. Malaysia
8. Indonesia
9. New Zealand

Latin America

1. Brazil
2. Mexico
3. Argentina

Middle East & Africa

1. South Africa
2. Saudi Arabia
3. United Arab Emirates

All the Key players have been covered from 4 Viewpoints:

1. Overviews
2. Recent Developments
3. Product Portfolio
4. Revenue

Companies List

1. DuPont
2. Evelo Biosciences Inc.
3. Finch Therapeutics Group Inc.
4. Ginkgo Bioworks
5. Seres Therapeutics
6. AOBiome
7. Astarte Medical
8. Axial Biotherapeutics Inc.
9. Osel Inc.

Key Questions Answered in This Report:

Question:    How big is the Human Microbiome market?

Answer:     The global Human Microbiome market size was estimated to reach USD 3.05 billion in 2032 while it was estimated to reach US$ 0.72 billion by 2023.

Question:    What is the Human Microbiome market growth rate?

Answer:    The global Human Microbiome market is expected to grow at a compound annual growth rate of 17.48% from 2024 to 2032.

Question:    Who are the key players in Human Microbiome market?

Answer:    Some key players operating in the Human Microbiome market include DuPont, Evelo Biosciences Inc., Finch Therapeutics Group Inc, etc.

Question:    What are the factors driving the Human Microbiome market?

Answer:    Key factors that are driving the Human Microbiome market growth include the growing number of elderly people and the rising burden of lifestyle-related disorders are major drivers of this market's growth, Government programs and increased funding initiatives to promote this research are high-impact key factors expected to stimulate market expansion.

Question:    Which Region held the largest market share in the Human Microbiome market?

Answer:    “North America” had the largest share in the Human Microbiome Market.

Report Details: